

















# Commonly Prescribed HIV Medications




## Complete Regimens

<b>Biktarvy</b> (bictegravir/emtricitabine/tenofovir alafenamide) 	<b>Cabenuva</b> (cabotegravir + rilpivirine) 	<b>Delstrigo</b> (doravirine/lamivudine/tenofovir disoproxil fumarate) 	<b>Dovato</b> (dolutegravir + lamivudine) 	<b>Genvoya</b> (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide) 	<b>Juluca</b> (dolutegravir/rilpivirine) 	<b>Odefsey</b> (emtricitabine/rilpivirine/tenofovir alafenamide) 	<b>Symfi/Symfi Lo</b> (efavirenz/lamivudine/tenofovir disoproxil fumarate) 	<b>Symtuza</b> (darunavir/cobicistat/emtricitabine/tenofovir alafenamide) 	<b>Triumeq</b> (dolutegravir/abacavir/lamivudine) 
---	--	--	---	--	--	--	--	---	---





## Nucleoside/Nucleotide Analogs (NRTIs)

<b>Cimduo/Temixys</b> (lamivudine/tenofovir disoproxil fumarate) 	<b>Descovy</b> (emtricitabine/tenofovir alafenamide) 	<b>Emtriva</b> (emtricitabine or FTC) 	<b>Epivir</b> (lamivudine or 3TC) 	<b>Truvada</b> (emtricitabine/tenofovir disoproxil fumarate) 	<b>Viread</b> (tenofovir disoproxil fumarate or TDF) 
--	--	---	---	--	--




## Non-Nucleosides (NNRTIs)

<b>Edurant</b> (rilpivirine or RPV) 	<b>Intelence</b> (etravirine or ETV) 	<b>Pifeltro</b> (doravirine) 
---	--	--




## Protease Inhibitors (PIs)

<b>Evotaz</b> (atazanavir/cobicistat) 	<b>Prezcobix</b> (darunavir/cobicistat) 	<b>Prezista</b> (darunavir or DRV) 	<b>Reyataz</b> (atazanavir or ATV) 
---	---	---	--



## Pre-Exposure Prophylaxis (PrEP)

<b>Apretude</b> (cabotegravir) 	<b>Descovy</b> (emtricitabine/tenofovir alafenamide)  <p>Not indicated for individuals at risk from receptive vaginal sex.</p>	<b>Truvada</b> (emtricitabine/tenofovir disoproxil fumarate) 
--	---	--



## Integrase Inhibitors

<b>Isentress</b> (raltegravir or RAL) 	<b>Tivicay</b> (dolutegravir or DTG) 	<b>Vocabria</b> (cabotegravir) 
---	--	--

## Pharmacokinetic Enhancers

<b>Norvir</b> (ritonavir or RTV) 	<b>Tyboost</b> (cobicistat) 
--	---

## Entry Inhibitors

<b>Ruboika</b> (fostemsavir) 	<b>Trogarzo</b> (ibalizumab-uiyk)  <p>(for injection)</p>
--	--

## Capsid Inhibitor

<b>Sunleca</b> (lenavapavir)  <p>(for injection)</p>
---

# Infrequently Prescribed or Discontinued HIV Medications


## Non-Nucleosides (NNRTIs)


**Rescriptor**  
(delavirdine or DLV)  


**Sustiva**  
(efavirenz or EFV)  


**Viramune**  
(nevirapine or NVP)  


## Entry Inhibitors

**Maraviroc**  


**Fuzeon**  
(enfuvirtide or ENF)  
(for injection)  


## Integrase Inhibitors

**Vitekta**  
(elvitegravir)  


## Nucleoside/Nucleotide Analogs (NRTIs)

**Combivir**  
(zidovudine/lamivudine)  


**Epzicom**  
(abacavir/lamivudine)  



**Retrovir**  
(zidovudine ZDV or AZT)  


**Trizivir**  
(abacavir/lamivudine/zidovudine)  



**Videx, Videx EC**  
(didanosine or ddl)  



**Zerit**  
(stavudine or d4T)  



## Nucleoside/Nucleotide Analogs (NRTIs) cont.

**Ziagen**  
(abacavir or ABC)  



## Complete Regimens


**Atripla**  
(efavirenz/emtricitabine/tenofovir disoproxil fumarate)  



**Complera**  
(rilpivirine/emtricitabine/tenofovir disoproxil fumarate)  



**Stribild**  
(elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate)  



## Protease Inhibitors (PIs)


**Aptivus**  
(tipranavir or TPV)  


**Crixivan**  
(indinavir or IDV)  


**Invirase**  
(saquinavir or SQV)  


**Kaletra**  
(lopinavir/ritonavir)  


**Lexiva**  
(fosamprenavir or FPV)  


**Viracept**  
(nelfinavir or NFV)  


**Community Resource Initiative (CRI)** is an independent, nonprofit, community-based organization dedicated to ending the HIV epidemic through **Research, Prevention, Access to Treatment, and Impact.**



Since 1989, CRI has produced critical data that has contributed to the FDA approval of nearly all of the currently available HIV treatments and forever changed the direction of HIV/AIDS treatment around the world.

Through its management of the Massachusetts Infectious Disease Drug Assistance Program (IDDAP)<sup>1</sup>, CRI provides access to medications and health insurance coverage to Massachusetts residents living with HIV or taking preventive treatment. Through its continued outreach efforts, CRI provides the latest treatment information to people living with HIV, hepatitis C, and other infectious diseases.

### About the medication chart:

CRI produces the medication chart with funding from the Bureau of Infectious Disease, Office of HIV/AIDS, Massachusetts Department of Public Health. It displays or names all formulations of each HIV or HCV medication currently or recently available. Medications on the chart are listed in the following manner:

- ▶ Grouped by class
- ▶ Commercial brand name in **bold**
- ▶ Formal clinical name (in parentheses), which may also be the name used in studies/trials before a medication received FDA approval and became available to the public

CRI updates the chart as needed, with the date of each version noted. Copies are available upon request. For more information or to order copies of the chart, please contact CRI Development and Communications at [info@crihealth.org](mailto:info@crihealth.org) or 617.502.1726.

**Visit our website at [www.crihealth.org](http://www.crihealth.org)**

<sup>1</sup> A program of the Massachusetts Department of Public Health.

529 Main Street, Suite 301, Boston, MA 02129  
617.502.1700

# HIV Medication Chart

Current as of 06/24

617.502.1700 | [www.crihealth.org](http://www.crihealth.org)

Produced with support from the Bureau of Infectious Disease, Office of HIV/AIDS, Massachusetts Department of Public Health.  
© 06/24